Stock Research: Aurobindo Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Aurobindo Pharma

NSEI:AUROPHARMA INE406A01037
63
  • Value
    31
  • Growth
    53
  • Safety
    Safety
    83
  • Combined
    66
  • Sentiment
    48
  • 360° View
    360° View
    63
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Aurobindo Pharma Limited is an India-based pharmaceutical company. It operates in the pharmaceuticals industry, focusing on active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company markets its products globally in approximately 150 countries. In the last fiscal year, the company had a market cap of $7790 million, profits of $2188 million, and revenue of $3713 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 63 (better than 63% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aurobindo Pharma are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Aurobindo Pharma. The consolidated Value Rank has an attractive rank of 83, which means that the share price of Aurobindo Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 83% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 53, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 48. Professional investors are more confident in 52% other stocks. Worryingly, the company has risky financing, with a Safety rank of 31. This means 69% of comparable companies have a safer financing structure than Aurobindo Pharma. ...read more

more
Index
Good Governace Growth Markets
Independent Boards Growth Markets
Low Waste
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
83 75 73 83
Growth
53 67 79 37
Safety
Safety
31 41 43 81
Sentiment
48 59 53 33
360° View
360° View
63 73 84 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
70 64 64 74
Opinions Change
50 37 53 50
Pro Holdings
n/a 72 45 16
Market Pulse
21 18 38 35
Sentiment
48 59 53 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
83 75 73 83
Growth
53 67 79 37
Safety Safety
31 41 43 81
Combined
66 83 85 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
83 81 82 89
Price vs. Earnings (P/E)
77 73 82 87
Price vs. Book (P/B)
81 73 80 86
Dividend Yield
37 39 34 36
Value
83 75 73 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
60 56 38 33
Profit Growth
39 42 88 58
Capital Growth
89 52 29 84
Stock Returns
17 73 100 7
Growth
53 67 79 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
29 32 40 42
Refinancing
85 78 82 90
Liquidity
23 38 40 76
Safety Safety
31 41 43 81

Similar Stocks

Discover high‑ranked alternatives to Aurobindo Pharma and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.